Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-13, Stock:ABBV, The news for the past five days is as follows:
2019-02-06: NEWS1: At least four pharma CEOs to testify at Senate drug pricing hearing.NEWS2: At least four pharma CEOs to testify at Senate drug pricing hearing.NEWS3: Congress invites 7 drugmakers to testify at potentially hostile hearing on drug prices. Here's what they're saying.NEWS4: Flip the Script: Drugmakers Blame Middlemen for Price Increases.NEWS5: 3 Biotech Stocks That Pay Solid Dividends.NEWS6: 3 Biotech Stocks That Pay Solid Dividends.
2019-02-07: NEWS1: Is AbbVie or Celgene Expected to Report Faster Revenue Growth?.NEWS2: What Analysts Recommend for AbbVie and Celgene This Month.NEWS3: ABBV March 29th Options Begin Trading.NEWS4: ABBV March 29th Options Begin Trading.NEWS5: Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript.
2019-02-08: NEWS1: Does FedEx look good here? What's the deal with McKesson? Buy Abbvie?.NEWS2: What Are the Key Growth Drivers for AbbVie in 2019?.NEWS3: AbbVie or Celgene: Which Is Controlling Its Expenses Better?.NEWS4: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS5: AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?.
2019-02-11: NEWS1: Here's Why Coherus BioSciences Rose 48.7% in January.NEWS2: Here's Why Coherus BioSciences Rose 48.7% in January.NEWS3: 5 High-Growth Stocks Undervalued by the Market.NEWS4: Here&apos;s Why Coherus BioSciences Rose 48.7% in January.NEWS5: IWV, PEP, ABBV, AMGN: ETF Outflow Alert.NEWS6: IWV, PEP, ABBV, AMGN: ETF Outflow Alert.NEWS7: AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma.NEWS8: ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt.
2019-02-12: NEWS1: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS2: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS3: Better Buy: Gilead Sciences vs. Pfizer.NEWS4: Better Buy: Gilead Sciences vs. Pfizer.NEWS5: AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma.NEWS6: 5 Aristocrats for Stable Income.NEWS7: 5 High-Growth Stocks Undervalued by the Market.NEWS8: 5 High-Growth Stocks Undervalued by the Market.

Answer: Rise